MS and Demyelinating Disorders

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 22, 2020.

The director of the multiple sclerosis research unit at Ottawa Hospital discussed stem cell therapies being explored in multiple sclerosis, and which patients may be eligible for these treatments.

The first study to examine the impact on real-world outcomes and costs of switching patients with MS from Copaxone to Glatopa revealed few significant differences.

The chief of the Division of Neurology at Children’s Hospital of Philadelphia spoke to the need for clinical trial evidence and research for the pediatric MS population.

The director of behavioral medicine at the Mellen Center for MS Treatment and Research at Cleveland Clinic discussed the importance of interdisciplinary care and ways it can be incorporated for patients with multiple sclerosis.

In addition to the 2020 CMSC Virtual Meeting, attendees will be eligible to earn up to an additional 18 contact hours of continuing education.

Recipients of the award will be provided additional funding that will go to support porgrams for MS patients and their care partners.

The neurologist at the Mellen Center for Multiple Sclerosis Treatment and Research at Cleveland Clinic discussed how the agent might fit into the treatment landscape if its sBLA is approved by the FDA later this year.

Women with multiple sclerosis had a greater risk of macrovascular disease than men, which was consistent with previous studies.

With an FDA decision on a BLA for the Genentech agent expected later this year, the Group Medical Director of Neuroscience at Genentech shared insight on recent findings of satralizumab in NMOSD.

Neurology News Network for the week ending May 16, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 15, 2020.

The data from the SAkuraStar study on satralizumab add to the total literature on the Genentech humanized monoclonal antibody, which is set for FDA decision later this year.